Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7):
A randomized, multicentre, open-label, phase 3 trial
To assess whether a weekly schedule of carboplatin plus paclitaxel is more effective than the same drug combination given every 3 weeks
Type of study
Randomised controlled trial (RCT)
Weekly vs every 3 weeks regimens of Carboplatin plus Paclitaxel
Experimental arm (Intervention)
Weekly Carboplatin plus Paclitaxel
Standard Carboplatin plus Paclitaxel every 3 weeks
- Quality of Life
- Progression-free survival
- Overall survival
- Toxic effects
- The proportion of patients who achieved an objective response
- Women older than 18 years of age
- Cytological or histological diagnosis of the epithelial ovarian, fallopian tube, or peritoneal cancer
- Stage IC – IV disease (Based on FIGO)
- Eastern Cooperative Oncology Group (ECOG) performance status of 2 or lower
- Life Expectancy of at least 3 months
- Adequate bone marrow, kidney, and liver functions
- History of clinically relevant heart disease or any disorders that pose contraindications to treatment drugs.
- Previous or concomitant malignant disease (except non-melanoma skin cancer or in-situ carcinoma of the uterine cervix)
- Previous history of chemotherapy
*No significant difference between groups was found on multivariate analysis. Residual disease and FIGO stage were independent predictors of progression-free survival.
The proposed weekly regimen of carboplatin and paclitaxel improves quality of life and has a better toxicity profile yet it does not alter progress-free or overall survival. Despite how challenging it to adhere to and provide such regimen, it is a reasonable alternative first-line treatment for advanced ovarian cancer.
The study’s sample is not representative enough to account for differences in treatment endpoints such as those caused by genetic polymorphism. In addition, the usage of consistent dosing to accurately predict treatment effect might have led to inefficient and ineffective outcomes.